Comparison of more and less lipophilic serotonin (5HT(1B/1D)) agonists in a model of trigeminovascular nociception in cat

Experimental Neurology

Volumn 150, Issue 1, 1998, Pages 45-51

  Hoskin, Karen L ^a   Goadsby, Peter J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Blood brain barrier; Headache; Migraine; Sumatriptan; Zolmitriptan

Indexed keywords

CHLORALOSE; GALLAMINE TRIETHIODIDE; HALOTHANE; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CAT; CONTROLLED STUDY; ELECTROSTIMULATION; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MIGRAINE; NOCICEPTION; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; SPINAL CORD DORSAL HORN; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS;

EID: 0032032630     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6749     Document Type: Article

References (54)

1. 1D. Cephalalgia. 15:1995;203.
2. Berman A. L. The Brain Stem of the Cat: A Cytoarchitectonic Atlas with Stereotaxic Co-ordinates. 1968;University of Wisconsin Press, London.
3. Connor H. E., O'Shaughnessy C. T., Feniuk W., Perren M. J., North P. C., Oxford A. W., Butina D., Owen M., Humphrey P. P. A. GR85548: A potent selective agonist for the intracranial vascular 5-HT1 receptor. Br. J. Pharmacol. 108:1993;99P.
4. Cumberbatch M. J., Hill R. G., Hargreaves R. J. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. 328:1997;37-40.
5. Cutrer F. M., Limmroth V., Ayata G., Moskowitz M. A. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br. J. Pharmacol. 116:1995;3199-3204.
6. Feindel W., Penfield W., McNaughton F. The tentorial nerves and localisation of intracranial pain in man. Neurology. 10:1960;555-563.
7. Feniuk W., Humphrey P. P. A., Perren M. J., Connor H. E., Whalley E. T. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J. Neurol. 238:1991;S57-S61.
8. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Trequattrini A., Palumbo R. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 15:1995;384-390.
9. Goadsby P. J. The challenge of headache for the nineties. Curr. Opin. Neurol. 7:1994;255-282.
10. Goadsby P. J. Bench to bedside: What have we learnt recently about headache. Curr. Opin. Neurol. 10:1997;215-220.
11. Goadsby P. J., Duckworth J. W. Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am. J. Physiol. 253:1987;R270-R274.
12. Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann. Neurol. 33:1993;48-56.
13. Goadsby P. J., Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 34:1994;394-399.
14. Goadsby P. J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28:1990;183-187.
15. 3. Ann. Neurol. 29:1991;91-94.
16. Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): Are brain stem sites a therapeutic target in migraine. Pain. 67:1996;355-359.
17. Goadsby P. J., Hoskin K. L. The distribution of trigeminovascular afferents in the non-human primate brainmacaca nemestrina: J. Anat. 190:1997;367-375.
18. Goadsby P. J., Knight Y. E. Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat. Cephalalgia. 17:1997;153-158.
19. 1B/1D. Br. J. Pharmacol: 122:1997;918-922.
20. Goadsby P. J., Silberstein S. D. Headache. 1997;Butterworth-Heinemann, New York.
21. Goadsby P. J., Zagami A. S., Lambert G. A. Neural processing of craniovascular pain: A synthesis of the central structures involved in migraine. Headache. 31:1991;365-371.
22. Goldstein J., Dahlof C. G. H., Diener H.-C., Olesen J., Schellens R., Senard J. M., Simard D., Steiner T. J. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. Cephalalgia. 16:1996;497-502.
23. 1D. Cephalalgia. 16:1996;386.
24. 1b. J. Pharmacol. Exp. Ther. 243:1987;989-1001.
25. Hammond D. L., Presley R., Gogas K. R., Bausbaum A. I. Morphine suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J. Comp. Neurol. 315:1992;244-253.
26. Hoskin K. L., Kaube H., Goadsby P. J. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos. Brain. 119:1996;249-256.
27. Hoskin K. L., Kaube H., Goadsby P. J. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain. 119:1996;1419-1428.
28. Hoskin K. L., Knight Y. E., Goadsby P. J. Zolmitriptan inhibits c-Fos expression in the dorsal horn of the medulla and upper cervical horn evoked by sagittal sinus stimulation in the cat. Cephalalgia. 16:1996;355.
29. Humphrey P. P. A., Feniuk W., Marriott A. S., Tanner R. J. N., Jackson M. R., Tucker M. L. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. 31:1991;282-290.
30. Humphrey P. P. A., Goadsby P. J. Controversies in headache: The mode of action of sumatriptan is vascular? A debate. Cephalalgia. 14:1994;401-410.
31. Hunt S. P., Pini A., Evan G. Induction of c-fos like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;1686-1704.
32. Kaube H., Hoskin K. L., Goadsby P. J. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol. 109:1993;788-792.
33. Kaube H., Keay K., Hoskin K. L., Bandler R., Goadsby P. J. Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res. 629:1993;95-102.
34. Keller J. T., Marfurt C. F., Dimlich R. V., Tierney B. E. Sympathetic innervation of the supratentorial dura mater of the rat. J. Comp. Neurol. 290:1989;310-321.
35. Knight Y. E., Edvinsson L., Goadsby P. J. Blockade of release of CGRP after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122,288. Cephalalgia. 17:1997;248.
36. 33. Mol. Pharmacol. 50:1996;1567-1580.
37. Liu-Chen L.-Y., Gillespie S. A., Norregaard T. V., Moskowitz M. A. Co-localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral. J. Comp. Neurol. 225:1984;187-192.
38. 1B/D. Neurology. 48:1997;A67.
39. 1B/1D. Br. J. Pharmacol. 121:1997;157-164.
40. McNaughton F. L. The innervation of the intracranial blood vessels and the dural sinuses. The Circulation of the Brain and Spinal Cord. 1966;Hafner, New York. p. 178-200.
41. 3. Eur. J. Pharmacol. 280:1995;175-178.
42. Moskowitz M. A., Cutrer F. M. Sumatriptan: A receptor-targeted treatment for migraine. Annu. Rev. Med. 44:1993;145-154.
43. Penfield W. A contribution to the mechanism of intracranial pain. Proc. Assoc. Res. Nerv. Mental Dis. 15:1934;399-415.
44. 1F. Proc. Soc. Neurosci. 22:1996;1331.
45. Ray B. S., Wolff H. G. Experimental studies on headache: Pain sensitive structures of the head and their significance in headache. Arch. Surg. 41:1940;813-856.
46. Rexed B. A cytoarchitectonic atlas of the spinal cord in the cat. J. Comp. Neurol. 96:1954;297-380.
47. 1B/1D. Cephalalgia. 17:1997;849-854.
48. Shepheard S. L., Williamson D. J., Williams J., Hill R. G., Hargreaves R. J. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology. 34:1995;255-261.
49. Siegel S. Non-parametric Statistics for the Behavioural Sciences. 1956;McGraw-Hill, Kogakusha/Tokyo.
50. Sleight A. J., Cervenka A., Peroutka S. J. In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology. 29:1990;511-513.
51. Spencer S. E., Sawyer W. B., Wada H., Platt K. B., Loewy A. D. CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: A retrograde transneuronal viral cell body labeling study. Brain Res. 534:1990;149-169.
52. 3. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;263-275.
53. Winner P., Ricalde O., Force B. L., Saper J., Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch. Neurol. 53:1996;180-184.
54. Wolff, H. G. 1963, Headache and Other Head Pain, Oxford Univ. Press, New York.